Haoyuan Pharmaceutical and UVLEDTEK form a strong alliance, Open a new era of continuous flow drug synthesis technology

2025 year 7 moon 23 day, Shanghai Haoyuan Pharmaceutical Co., Ltd (stock code: 688131, hereinafter referred to as "Haoyuan Pharmaceutical" ) Wuhan UVLEDTEK Technology Co., Ltd (hereinafter referred to as "UVLEDTEK" ) Signed a strategic cooperation agreement officially in Shanghai. This in-depth cooperation will focus on the innovative application of third-generation wide bandgap semiconductors in the field of optical continuous flow drug synthesis, By integrating the core advantages of both parties in the fields of chemical synthesis and semiconductor optical technology, Promoting drug production through momentum transfer, HEAT TRANSFER, Achieving a qualitative leap in quality transfer and chemical reaction efficiency, Accelerate the pharmaceutical manufacturing industry from traditional "batch production" to, toward, at, facing "Continuity, Intelligent, low-carbon" The leapfrog upgrade, Establishing a new benchmark for global pharmaceutical research and production.

as CDMO Leading enterprises in the field, Haoyuan Pharmaceutical deeply cultivates small molecule drugs, ADC For many years, we have been involved in the research, development, and production of drugs and other related fields, Built coverage "starting material - intermediate - API (Active Pharmaceutical Ingredient) - preparation" Integrated service capability, at ADC Drug development and CDMO The field is in the top tier of the industry. as of now, The company has served the global super 990 Home Customers, support 50 More than one CMC Project and 150 Remaining loads - Connecting sub projects, 2019 Year to 2024 Annual revenue from 4. 09 Billion yuan growth to 22. 7 RMB100mn, Annual average growth rate maintained 40% left and right, Continuously empowering the global pharmaceutical research and development process with strong innovation capabilities.

UVLEDTEK is the only domestic company that has achieved third-generation semiconductor ultraviolet technology LED full spectrum, Pioneer enterprise in the layout of the entire industry chain, Having a complete technical system from epitaxial material growth to light source system integration. Its independently developed deep ultraviolet chip technology achieves full spectrum coverage, The performance indicators such as chip light efficiency have reached the global leading level, Accumulated applications 325 Intellectual Property Rights, Improve UV efficiency, Reliability optimization and system integration, Forming unique core competitiveness in the application of artificial intelligence algorithms and other aspects, The product has been widely used in new energy vehicles, healthcare, Key areas such as high-end manufacturing.

Dr. Zheng Baofu, Chairman of Haoyuan Pharmaceutical: "The pharmaceutical industry is currently in a critical period of technological transformation, Optical continuous flow synthesis technology relies on its high efficiency, The advantages of green, Expected to reconstruct the drug production model. UVLEDTEK in UV LED Top technological strength in the field of chip and system integration, Deeply connected with Haoyuan Pharmaceutical CDMO Industrialization capabilities form perfect complementarity. This cooperation will accelerate the landing and transformation of manufacturing technology in the pharmaceutical field, Assist global partners in advanced manufacturing to shorten the drug development cycle, Bring more efficient treatment options to patients, Promote the development of the pharmaceutical industry towards higher quality. "

The achievement of this strategic cooperation, This is an important measure for both parties to integrate complementary resources in the fields of chemical synthesis and semiconductor optical technology. Exploring the technological innovation of third-generation wide bandgap semiconductors in the continuous flow drug synthesis process through joint efforts, Both parties will transfer momentum, HEAT TRANSFER, Realize qualitative improvement in quality transfer and chemical reaction efficiency, Promote the completion of pharmaceutical manufacturing from "batch production" to, toward, at, facing "Continuity, Intelligent, low-carbon" The leapfrog upgrade and transformation. This cooperation not only opens a new chapter in pharmaceutical manufacturing technology innovation, Establishing a new benchmark for technological innovation and green development in the pharmaceutical manufacturing industry, Will contribute significantly to the progress of the global pharmaceutical industry.